The impact of bolus on clinical outcomes for post-mastectomy breast cancer patients treated with IMRT: data from China.

IF 3.3 2区医学 Q2 ONCOLOGY

Radiation Oncology Pub Date : 2024-05-28 DOI:10.1186/s13014-024-02456-z

Tao Jiang, Jiao Tian, Peijie Lei, Chunliu Meng, Jialei Fu, Lianjing Cao, Jingjing Cheng, Fei Zhou, Hongjun Zhang, Hao Song, Haijun Lu, Xiaojuan Wei

{"title":"The impact of bolus on clinical outcomes for post-mastectomy breast cancer patients treated with IMRT: data from China.","authors":"Tao Jiang, Jiao Tian, Peijie Lei, Chunliu Meng, Jialei Fu, Lianjing Cao, Jingjing Cheng, Fei Zhou, Hongjun Zhang, Hao Song, Haijun Lu, Xiaojuan Wei","doi":"10.1186/s13014-024-02456-z","DOIUrl":null,"url":null,"abstract":"Purpose: This study aims to investigate the effects of chest wall bolus in intensity-modulated radiotherapy (IMRT) technology on clinical outcomes for post-mastectomy breast cancer patients.Materials and methods: This retrospective study included patients with invasive carcinoma ((y)pT0-4, (y)pN0-3) who received photon IMRT after mastectomy at the Affiliated Hospital of Qingdao University from 2014 to 2019. The patients were divided into two groups based on whether they received daily bolus application or not, and the baseline characteristics were matched using propensity score matching (PSM). Cumulative incidence (CI) of local recurrence (LR), locoregional recurrence (LRR), overall survival (OS) and disease-free survival (DFS) were evaluated with a log-rank test. Acute skin toxicity and late radiation pneumonia was analyzed using chi-square test.Results: A total of 529 patients were included in this study, among whom 254 (48%) patients received bolus application. The median follow-up time was 60 months. After matching, 175 well-paired patients were selected. The adjusted 5-year outcomes (95% confidence interval) in patients treated with and without bolus were, respectively: CI of LR 2.42% (0.04-4.74) versus 2.38% (0.05-4.65), CI of LRR 2.42% (0.04-4.74) versus 3.59% (0.73-6.37), DFS 88.12% (83.35-93.18) versus 84.69% (79.42-90.30), OS 94.21% (90.79-97.76) versus 95.86% (92.91-98.91). No correlation between bolus application and skin toxicity (P = 0.555) and late pneumonia (P = 0.333) was observed.Conclusions: The study revealed a low recurrence rate using IMRT technology. The daily used 5 mm chest wall bolus was not associated with improved clinical outcomes.","PeriodicalId":49639,"journal":{"name":"Radiation Oncology","volume":null,"pages":null},"PeriodicalIF":3.3000,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11134933/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiation Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13014-024-02456-z","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: This study aims to investigate the effects of chest wall bolus in intensity-modulated radiotherapy (IMRT) technology on clinical outcomes for post-mastectomy breast cancer patients.

Materials and methods: This retrospective study included patients with invasive carcinoma ((y)pT0-4, (y)pN0-3) who received photon IMRT after mastectomy at the Affiliated Hospital of Qingdao University from 2014 to 2019. The patients were divided into two groups based on whether they received daily bolus application or not, and the baseline characteristics were matched using propensity score matching (PSM). Cumulative incidence (CI) of local recurrence (LR), locoregional recurrence (LRR), overall survival (OS) and disease-free survival (DFS) were evaluated with a log-rank test. Acute skin toxicity and late radiation pneumonia was analyzed using chi-square test.

Results: A total of 529 patients were included in this study, among whom 254 (48%) patients received bolus application. The median follow-up time was 60 months. After matching, 175 well-paired patients were selected. The adjusted 5-year outcomes (95% confidence interval) in patients treated with and without bolus were, respectively: CI of LR 2.42% (0.04-4.74) versus 2.38% (0.05-4.65), CI of LRR 2.42% (0.04-4.74) versus 3.59% (0.73-6.37), DFS 88.12% (83.35-93.18) versus 84.69% (79.42-90.30), OS 94.21% (90.79-97.76) versus 95.86% (92.91-98.91). No correlation between bolus application and skin toxicity (P = 0.555) and late pneumonia (P = 0.333) was observed.

Conclusions: The study revealed a low recurrence rate using IMRT technology. The daily used 5 mm chest wall bolus was not associated with improved clinical outcomes.

查看原文本刊更多论文

栓剂对接受 IMRT 治疗的乳腺癌切除术后患者临床疗效的影响：来自中国的数据。

目的：本研究旨在探讨调强放疗（IMRT）技术中的胸壁栓剂对乳腺癌切除术后患者临床疗效的影响：该回顾性研究纳入了2014年至2019年在青岛大学附属医院接受乳腺癌切除术后光子IMRT治疗的浸润癌患者（（y）pT0-4，（y）pN0-3）。根据是否接受每日栓剂应用将患者分为两组，并通过倾向评分匹配（PSM）对基线特征进行匹配。采用对数秩检验评估局部复发（LR）、局部区域复发（LRR）、总生存期（OS）和无病生存期（DFS）的累积发生率（CI）。急性皮肤毒性和晚期放射性肺炎采用卡方检验进行分析：本研究共纳入了 529 例患者，其中 254 例（48%）患者接受了栓剂治疗，中位随访时间为 60 个月。中位随访时间为 60 个月。经过配对，选出了 175 名配对成功的患者。接受和未接受栓剂治疗的患者的调整后 5 年结果（95% 置信区间）分别为LR的CI为2.42%（0.04-4.74）对2.38%（0.05-4.65），LRR的CI为2.42%（0.04-4.74）对3.59%（0.73-6.37），DFS为88.12%（83.35-93.18）对84.69%（79.42-90.30），OS为94.21%（90.79-97.76）对95.86%（92.91-98.91）。没有观察到栓剂应用与皮肤毒性（P = 0.555）和晚期肺炎（P = 0.333）之间的相关性：研究显示，使用 IMRT 技术的复发率较低。结论：该研究显示，使用 IMRT 技术的复发率较低，日常使用的 5 毫米胸壁栓剂与临床疗效的改善无关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Radiation Oncology ONCOLOGY-RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

CiteScore

6.50

自引率

2.80%

发文量

181

审稿时长

3-6 weeks

期刊介绍： Radiation Oncology encompasses all aspects of research that impacts on the treatment of cancer using radiation. It publishes findings in molecular and cellular radiation biology, radiation physics, radiation technology, and clinical oncology.

文献相关原料

公司名称	产品信息	采购帮参考价格